The potential carcinogenic role of EGF therapy in the intestine remains to be addressed because EGF may be implicated in tumorigenesis as well as in targeted treatment for colorectal cancer,[20, 21] esophageal cancer,[22] head and neck cancer,[23] hepatocellular carcinoma,[24] pancreatic cancer,[25] non-small cell lung cancer,[26, 27] malignant glioma[28] and breast cancer,[29] among others. This evidence concerns the gene EGF and hepatocellular carcinoma.